MYBL2 maintains stemness and promotes theta-mediated end joining in triple negative breast cancer
Bayley, R.; Munsey, A.; Ahmed, S.; Ward, C.; Stiby, A.; Briantseva, B.-M.; Jawanda, K.; Shaaban, A. M.; Saponaro, M.; Smith, G. C. M.; Clarke, R. B.; Davies, C.; Garcia, P.
Show abstract
Triple negative breast cancer (TNBC) has a poor prognosis due to limited treatment options and high metastasis risk. Breast cancer (BC) stem/progenitor cells, also known as tumour initiating cells, are a small, difficult to target population within the tumour responsible for metastasis and therapy resistance. MYBL2 overexpression is commonly linked to poor prognosis and metastasis but its role in BC stem/progenitor cells remains elusive. To determine the role of MYBL2 in BC stem/progenitor cells we generated TNBC cell lines with inducible MYBL2 downregulation. Our findings reveal that elevated MYBL2 is essential for self-renewal, DNA repair, and replication stress response in these cells and lowering MYBL2 impairs stemness and self-renewal both in vitro and in vivo. Accordingly, our functional and mechanistic analyses indicate that high-MYBL2 stem/progenitor cells exhibit increased sensitivity to Pol{theta} inhibitors which is lost upon MYBL2 downregulation due to transcriptional suppression. Combining Pol{theta} inhibitors with ATR inhibitors further enhances this sensitivity, in vitro and ex vivo. This study thus identifies Pol{theta}/ATR inhibition as a synthetic lethality strategy to eradicate BC stem/progenitor cells and underscores MYBL2 expression as a biomarker for patient stratification in this treatment.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A SNAI2-PEAK1 stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting a cytokine expression profile that converges on PI3K/Akt signaling 95%
- Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer 95%
- Polyploid cancer cells reveal signatures of chemotherapy resistance 94%
Similar papers in this journal
- Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibition 94%
- Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics 93%
- EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas 93%
Similar papers in this journal
- Integrative analysis of patient-derived tumoroids and ex vivo organoid modeling of ARID1A loss in bladder cancer reveals therapeutic molecular targets 94%
- ADAM protease inhibition overcomes resistance of breast cancer stem-like cells to γδ T cell immunotherapy 93%
- IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors 93%
Similar papers in this journal
- Single cell transcriptomics reveals involution mimicry during the specification of the basal breast cancer subtype 94%
- Transcriptional Control of Brain Tumour Stem Cell by a Carbohydrate Binding Protein 93%
- MAPK14/p38α Shapes the Molecular Landscape of Endometrial Cancer and promotes Tumorigenic Characteristics 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.